ACLACINOMYCIN A
Aclacinomycin A is an anthracycline antibiotic that inhibits DNA and RNA synthesis by intercalating into nucleic acids and disrupting polymerase activity. It is used primarily in the treatment of leukemia. Benefits include potent antitumor activity with reduced cardiotoxicity compared to some related anthracyclines. Side effects include myelosuppression, gastrointestinal disturbances, mucositis, and mild cardiotoxicity, requiring careful dose monitoring and supportive care during therapy.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Aclacinomycin A (also known as aclarubicin) is an anthracycline antineoplastic antibiotic. It intercalates into DNA, inhibits topoisomerase II and generates free radicals, leading to disruption of DNA replication and repair and ultimately cell death, particularly in rapidly dividing cells.
Benefits and advantages
Aclacinomycin A has been used in the treatment of certain haematological malignancies, such as acute myeloid leukaemia, often in combination regimens. Compared with some other anthracyclines, it may exhibit a different toxicity profile, including potentially reduced cardiotoxicity at therapeutic doses.
Side effects and risks
As with other anthracyclines, dose‑limiting toxicities include myelosuppression, mucositis and alopecia. Cumulative cardiotoxicity with risk of congestive heart failure remains a concern, particularly at higher total doses or in susceptible patients. Extravasation can cause severe local tissue injury. Handling requires strict cytotoxic‑drug safety procedures.
Professional use only. This cytostatic API is supplied exclusively to licensed oncology centres and manufacturers.
Datasheet
| Molecular Formula | C42H53NO15 |
|---|---|
| Molecular Weight | 811.9 g/mol |
| CAS Number | 57576-44-0 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | aclarubicin; Aclacinomycin A; 57576-44-0; Aclarubicine; Aclarubicinum |
| IUPAC/Chemical Name | methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate |
| InChl Key | USZYSDMBJDPRIF-SVEJIMAYSA-N |
| InChl Code | InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
